These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 22770604)

  • 81. Recommendations for the Assessment and Management of Pre-existing Drug-Reactive Antibodies During Biotherapeutic Development.
    Xue L; Clements-Egan A; Amaravadi L; Birchler M; Gorovits B; Liang M; Myler H; Purushothama S; Manning MS; Sung C
    AAPS J; 2017 Nov; 19(6):1576-1586. PubMed ID: 29110222
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Testing human biologicals in animal host resistance models.
    Burleson GR; Burleson FG
    J Immunotoxicol; 2008 Jan; 5(1):23-31. PubMed ID: 18382855
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Considerations in the Immunogenicity Assessment Strategy for Oligonucleotide Therapeutics (ONTs).
    Bano N; Ehlinger C; Yang TY; Swanson M; Allen S
    AAPS J; 2022 Aug; 24(5):93. PubMed ID: 36028587
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Protein aggregation and immunogenicity of biotherapeutics.
    Pham NB; Meng WS
    Int J Pharm; 2020 Jul; 585():119523. PubMed ID: 32531452
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Development and optimization of neutralizing antibody assays to monitor clinical immunogenicity.
    Civoli F; Kroenke MA; Reynhardt K; Zhuang Y; Kaliyaperumal A; Gupta S
    Bioanalysis; 2012 Nov; 4(22):2725-35. PubMed ID: 23210655
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Challenges related to the immunogenicity of parenteral recombinant proteins: Underlying mechanisms and new approaches to overcome it.
    Faraji F; Karjoo Z; Moghaddam MV; Heidari S; Emameh RZ; Falak R
    Int Rev Immunol; 2018; 37(6):301-315. PubMed ID: 29851534
    [TBL] [Abstract][Full Text] [Related]  

  • 87. 10
    Tourdot S; Abdolzade-Bavil A; Bessa J; Broët P; Fogdell-Hahn A; Giorgi M; Jawa V; Kuranda K; Legrand N; Pattijn S; Pedras-Vasconcelos JA; Rudy A; Salmikangas P; Scott DW; Snoeck V; Smith N; Spindeldreher S; Kramer D
    MAbs; 2020; 12(1):1725369. PubMed ID: 32063088
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations.
    Shankar G; Arkin S; Cocea L; Devanarayan V; Kirshner S; Kromminga A; Quarmby V; Richards S; Schneider CK; Subramanyam M; Swanson S; Verthelyi D; Yim S;
    AAPS J; 2014 Jul; 16(4):658-73. PubMed ID: 24764037
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics.
    Wullner D; Zhou L; Bramhall E; Kuck A; Goletz TJ; Swanson S; Chirmule N; Jawa V
    Clin Immunol; 2010 Oct; 137(1):5-14. PubMed ID: 20708973
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Immune Suppression During Preclinical Drug Development Mitigates Immunogenicity-Mediated Impact on Therapeutic Exposure.
    Herskovitz J; Ryman J; Thway T; Lee S; Zhou L; Chirmule N; Meibohm B; Jawa V
    AAPS J; 2017 Mar; 19(2):447-455. PubMed ID: 28070711
    [TBL] [Abstract][Full Text] [Related]  

  • 91. War against Ourselves.
    Waldholz M
    Sci Am; 2017 Dec; 318(1):58-63. PubMed ID: 29257827
    [No Abstract]   [Full Text] [Related]  

  • 92. Biosimilars and biobetters as tools for understanding and mitigating the immunogenicity of biotherapeutics.
    Barbosa MD; Kumar S; Loughrey H; Singh SK
    Drug Discov Today; 2012 Dec; 17(23-24):1282-8. PubMed ID: 22796124
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The immunogenicity of therapeutic cytokines.
    Herzyk DJ
    Curr Opin Mol Ther; 2003 Apr; 5(2):167-71. PubMed ID: 12772507
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.
    Ponce R; Abad L; Amaravadi L; Gelzleichter T; Gore E; Green J; Gupta S; Herzyk D; Hurst C; Ivens IA; Kawabata T; Maier C; Mounho B; Rup B; Shankar G; Smith H; Thomas P; Wierda D
    Regul Toxicol Pharmacol; 2009 Jul; 54(2):164-82. PubMed ID: 19345250
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Scientific and regulatory considerations on the immunogenicity of biologics.
    Shankar G; Shores E; Wagner C; Mire-Sluis A
    Trends Biotechnol; 2006 Jun; 24(6):274-80. PubMed ID: 16631266
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Immunogenicity of biopharmaceuticals in laboratory animals.
    Wierda D; Smith HW; Zwickl CM
    Toxicology; 2001 Feb; 158(1-2):71-4. PubMed ID: 11164995
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins.
    Hamuro L; Kijanka G; Kinderman F; Kropshofer H; Bu DX; Zepeda M; Jawa V
    J Pharm Sci; 2017 Oct; 106(10):2946-2954. PubMed ID: 28576695
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Effects of protein aggregates: an immunologic perspective.
    Rosenberg AS
    AAPS J; 2006 Aug; 8(3):E501-7. PubMed ID: 17025268
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Safety issues specific to clinical development of protein therapeutics.
    Haller CA; Cosenza ME; Sullivan JT
    Clin Pharmacol Ther; 2008 Nov; 84(5):624-7. PubMed ID: 18701885
    [No Abstract]   [Full Text] [Related]  

  • 100. Statistical considerations for calculation of immunogenicity screening assay cut points.
    Hoffman D; Berger M
    J Immunol Methods; 2011 Oct; 373(1-2):200-8. PubMed ID: 21906599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.